Orchestra BioMed Statistics
Share Statistics
Orchestra BioMed has 38.01M shares outstanding. The number of shares has increased by 6.35% in one year.
| Shares Outstanding | 38.01M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.5% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 26.40M |
| Failed to Deliver (FTD) Shares | 151 |
| FTD / Avg. Volume | 0.16% |
Short Selling Information
The latest short interest is 703.15K, so 1.85% of the outstanding shares have been sold short.
| Short Interest | 703.15K |
| Short % of Shares Out | 1.85% |
| Short % of Float | 2.66% |
| Short Ratio (days to cover) | 12.57 |
Valuation Ratios
The PE ratio is -6.18 and the forward PE ratio is -3.22.
| PE Ratio | -6.18 |
| Forward PE | -3.22 |
| PS Ratio | 109.91 |
| Forward PS | 51.4 |
| PB Ratio | 4.46 |
| P/FCF Ratio | -6.57 |
| PEG Ratio | n/a |
Enterprise Valuation
Orchestra BioMed Inc. has an Enterprise Value (EV) of 274.47M.
| EV / Earnings | -5.59 |
| EV / Sales | 99.45 |
| EV / EBITDA | -5.36 |
| EV / EBIT | -5.33 |
| EV / FCF | -5.94 |
Financial Position
The company has a current ratio of 7.95, with a Debt / Equity ratio of 0.
| Current Ratio | 7.95 |
| Quick Ratio | 7.94 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.72% and return on capital (ROIC) is -73.86%.
| Return on Equity (ROE) | -0.72% |
| Return on Assets (ROA) | -0.52% |
| Return on Capital (ROIC) | -73.86% |
| Revenue Per Employee | 49.29K |
| Profits Per Employee | -877.14K |
| Employee Count | 56 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 1.27 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -27.05% in the last 52 weeks. The beta is 0.41, so Orchestra BioMed 's price volatility has been higher than the market average.
| Beta | 0.41 |
| 52-Week Price Change | -27.05% |
| 50-Day Moving Average | 5.39 |
| 200-Day Moving Average | 5.88 |
| Relative Strength Index (RSI) | 51.16 |
| Average Volume (20 Days) | 96.56K |
Income Statement
In the last 12 months, Orchestra BioMed had revenue of 2.76M and earned -49.12M in profits. Earnings per share was -1.48.
| Revenue | 2.76M |
| Gross Profit | 2.57M |
| Operating Income | -51.51M |
| Net Income | -49.12M |
| EBITDA | -51.22M |
| EBIT | -51.51M |
| Earnings Per Share (EPS) | -1.48 |
Balance Sheet
The company has 30.56M in cash and 1.69M in debt, giving a net cash position of 28.87M.
| Cash & Cash Equivalents | 30.56M |
| Total Debt | 1.69M |
| Net Cash | 28.87M |
| Retained Earnings | -248.85M |
| Total Assets | 75.32M |
| Working Capital | 52.34M |
Cash Flow
In the last 12 months, operating cash flow was -46.13M and capital expenditures -78.00K, giving a free cash flow of -46.20M.
| Operating Cash Flow | -46.13M |
| Capital Expenditures | -78.00K |
| Free Cash Flow | -46.20M |
| FCF Per Share | -1.39 |
Margins
Gross margin is 93.26%, with operating and profit margins of -1.87K% and -1.78K%.
| Gross Margin | 93.26% |
| Operating Margin | -1.87K% |
| Pretax Margin | -1.78K% |
| Profit Margin | -1.78K% |
| EBITDA Margin | -1.86K% |
| EBIT Margin | -1.87K% |
| FCF Margin | -1.67K% |
Dividends & Yields
OBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -28.14% |
| FCF Yield | -23.11% |
Analyst Forecast
The average price target for OBIO is $14.5, which is 175.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $14.5 |
| Price Target Difference | 175.7% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -2.91 |
| Piotroski F-Score | 2 |